June 3, 2021

Santen to Present Latest Data on Omidenepag Isopropyl at APGC 2021

Santen Pharmaceutical Co., Ltd. (Head Office in Osaka) announced today that some publications related to EP2 receptor agonist, omidenepag isopropyl will be presented at the 5th Asia-Pacific Glaucoma Congress (APGC 2021, https://www.apgc2021.org/), held virtually from June 4 to 8, 2021.

Omidenepag isopropyl was launched in Japan in 2018 as *EYBELIS Ophthalmic Solution 0.002%*, a treatment for glaucoma and ocular hypertension. It has been approved in several Asian countries and was launched in the Republic of Korea in February, 2021. Santen submitted the New Drug Application in the United States. (PDUFA[1] date: November 19, 2021, Development code: STN10117). At this conference, some presentation including the outcome of Phase 3 study in Asia will be conducted.
For information on these presentations, please see Medical Treatment Oral On-Demand Presentations under the following link.
https://apgc2021.org/program/#tabs_desc_1840_3

Presentation topics related to omidenepag isopropyl

Session number	Presentation title
145	Spectrum 6: Randomized Phase 2 trial evaluating the safety and efficacy of omidenepag isopropyl 0.002% once and twice daily dosing in subjects with primary open-angle glaucoma/ocular hypertension
174	Severity and time course of conjunctival hyperemia in subjects with open-angle glaucoma/ocular hypertension treated with omidenepag isopropyl
175	Comparison of omidenepag isopropyl 0.002% with latanoprost 0.005% in subjects with open-angle glaucoma/ocular hypertension: The Phase 3 PEONY Trial

1 Prescription Drug User Fee Act

Contact:
Investor Relations Group
Santen Pharmaceutical Co., Ltd.
E-mail: ir@santen.com